Axelrod Research — XOM: A 1.5% Pullback Still Does Not Create an Entry
XOM has slipped from the $166 level in my last review to $163.54 at the 18 September 2026 close, but the investment case has not improved enough to warrant fresh buying. Guyana remains the durable asset; the reported chemicals deal remains unconfirmed, and a 1.5% price change is not a thesis change.
XOM — HOLD
Why now. This is a quiet-day re-underwrite of an existing thesis. The stock closed at $163.54 on 18 September 2026, versus $166 in the 21 August 2026 review—a 1.5% decline over that comparison window. That is noise, not a margin of safety. The call remains HOLD.
The evidence. The August 2026 work separated two very different claims. Guyana's production and cost-recovery direction had support: Reuters reported on 18 August 2026 that Guyana was then entitled to nearly 40% of production, while the exact entitlement and timing remained dependent on contracts and actual output. By contrast, the reported bid of roughly $8bn for Shell chemicals assets had not been confirmed by either company as of the 28 August 2026 analysis. Exxon’s FY2025 results remain the latest primary financial anchor in that work; they do not turn an acquisition rumour into underwritten value. The 18 September 2026 market close changes none of those facts.
Levels and triggers. There is no price-only entry at $163.54. I would move to ACCUMULATE only if a new filing or company presentation supplies enough project and capital-allocation detail to establish an attractive return at the prevailing price—most importantly, confirmed Guyana production economics and, if a chemicals transaction occurs, purchase price, funding and accretion. Confirmation of the reported deal without those economics is not a catalyst. The thesis is killed if Guyana’s production or cost-recovery trajectory materially misses the issuer’s disclosed plan, or if a large acquisition weakens returns without a credible path to accretion.
Horizon. Six to twelve months, through the next several operating updates and any definitive transaction filing.
The bear case. The strongest case against even holding is that $163.54 already capitalises the high-quality Guyana runway while leaving shareholders exposed to oil-price cyclicality, refining and chemicals margins, and capital-allocation risk. If commodity prices weaken or management pays heavily for lower-return chemicals assets, the market can compress the valuation before Guyana volume offsets the damage.
What I’m watching: the next Exxon operating update for dated Guyana production and cost-recovery figures, plus any definitive filing on the reported Shell chemicals assets; either could change the call.
Sources
Independent equity analysis, for information only, not investment advice.